MY136382A - Use of cholesterol-lowering agent - Google Patents

Use of cholesterol-lowering agent

Info

Publication number
MY136382A
MY136382A MYPI20000415A MYPI20000415A MY136382A MY 136382 A MY136382 A MY 136382A MY PI20000415 A MYPI20000415 A MY PI20000415A MY PI20000415 A MYPI20000415 A MY PI20000415A MY 136382 A MY136382 A MY 136382A
Authority
MY
Malaysia
Prior art keywords
compound
cholesterol
lowering agent
lipid
pyramidin
Prior art date
Application number
MYPI20000415A
Other languages
English (en)
Inventor
Ali Raza
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY136382(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902590.0A external-priority patent/GB9902590D0/en
Priority claimed from GBGB9921062.7A external-priority patent/GB9921062D0/en
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of MY136382A publication Critical patent/MY136382A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
MYPI20000415A 1999-02-06 2000-02-04 Use of cholesterol-lowering agent MY136382A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9902590.0A GB9902590D0 (en) 1999-02-06 1999-02-06 Use of cholesterol-lowering agent
GBGB9921062.7A GB9921062D0 (en) 1999-09-08 1999-09-08 Use of cholestrol-lowering agent

Publications (1)

Publication Number Publication Date
MY136382A true MY136382A (en) 2008-09-30

Family

ID=26315084

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20000415A MY136382A (en) 1999-02-06 2000-02-04 Use of cholesterol-lowering agent

Country Status (22)

Country Link
EP (1) EP1150679A1 (id)
JP (2) JP2002536333A (id)
KR (1) KR100699287B1 (id)
CN (1) CN1347320A (id)
AR (1) AR022462A1 (id)
AU (1) AU769897B2 (id)
BR (1) BR0007991A (id)
CA (1) CA2358641A1 (id)
CZ (1) CZ20012631A3 (id)
EE (1) EE04659B1 (id)
HK (1) HK1040924A1 (id)
HU (1) HUP0105019A3 (id)
ID (1) ID30131A (id)
IL (1) IL144662A0 (id)
IS (1) IS5996A (id)
MY (1) MY136382A (id)
NO (1) NO319827B1 (id)
NZ (1) NZ512681A (id)
PL (1) PL349137A1 (id)
SK (1) SK11112001A3 (id)
TR (1) TR200102236T2 (id)
WO (1) WO2000045819A1 (id)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
SE0103509D0 (sv) * 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2007142581A1 (en) * 2006-06-07 2007-12-13 Astrazeneca Ab Combination product for the treatment or prevention of dyslipidaemia
CA2689525A1 (en) * 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
CA2689575A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
JP2010530417A (ja) * 2007-06-20 2010-09-09 メルク・シャープ・エンド・ドーム・コーポレイション ベンゾオキサゾールアリールアミドから誘導されたｃｅｔｐ阻害剤
EP2216095A1 (en) * 2009-01-27 2010-08-11 Koninklijke Philips Electronics N.V. Microfluidic device for full blood count

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260446A (en) * 1989-12-22 1993-11-09 Basf Aktiengesellschaft Aminothiazoles
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体

Also Published As

Publication number Publication date
CZ20012631A3 (cs) 2001-10-17
AU769897B2 (en) 2004-02-05
NO20013810L (no) 2001-10-03
HUP0105019A3 (en) 2003-02-28
JP2011137023A (ja) 2011-07-14
JP2002536333A (ja) 2002-10-29
NO20013810D0 (no) 2001-08-03
PL349137A1 (en) 2002-07-01
EE200100404A (et) 2002-10-15
BR0007991A (pt) 2001-11-06
EE04659B1 (et) 2006-08-15
KR20010089631A (ko) 2001-10-06
EP1150679A1 (en) 2001-11-07
NZ512681A (en) 2003-12-19
IL144662A0 (en) 2002-05-23
IS5996A (is) 2001-07-10
HUP0105019A2 (hu) 2002-05-29
KR100699287B1 (ko) 2007-03-26
ID30131A (id) 2001-11-08
NO319827B1 (no) 2005-09-19
TR200102236T2 (tr) 2001-12-21
AR022462A1 (es) 2002-09-04
CN1347320A (zh) 2002-05-01
CA2358641A1 (en) 2000-08-10
AU2305100A (en) 2000-08-25
WO2000045819A1 (en) 2000-08-10
SK11112001A3 (sk) 2002-02-05
HK1040924A1 (zh) 2002-06-28

Similar Documents

Publication Publication Date Title
IL155919A (en) (e) - 7 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - [methyl ( methylsulfonyl) amino] pyrimidin - 5 - yl] (3r, 5s) - dihydroxyhept - 6 - enoic acid, or a pharmaceutically acceptable salt thereof, for use as a medicament for the treatment of heterozygous familial hypercholesterolemia
CR10114A (es) Composiciones farmacéuticas que comprenden inhibidoras de la hmg coa reductasa (divisional del exp. 6687)
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
MY130157A (en) Method of use for inhibiting bone loss and lowering serum cholesterol
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
LT2001119A (en) Pharmaceutical formulations comprising intranasal morphine and use thereof
DE60323958D1 (de) Buprenorphin enthaltende zubereitung
WO2005056524A3 (en) Therapeutic agents useful for treating pain
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
TR200101633T2 (tr) Farmasötik bileşim
BG104797A (en) Use of dexmedetomi dine for sedative effect in patients in an intensive care unit
HK1040924A1 (zh) 降膽固醇劑的應用
EP1228758A4 (en) PROHYLACTIC AND THERAPEUTIC AGENTS FOR INFLAMMABLE COLON DISEASES
NO20063277L (no) Farmasoytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmate og anvendelse derav
WO2004018044A8 (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent
JP2002536333A5 (id)
MY134059A (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
RU2004112422A (ru) Роувастатин в преддеменционных состояниях
GEP20043377B (en) Pharmaceutical Complex
JP2005505605A5 (id)
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
TH68542A (th) การใช้สารลดโคเลสเตียรอล
BR0013921A (pt) Composições farmacêuticas para tratamento de psorìase
BR9913242A (pt) Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono